Press Releases

Press Releases

D.C. Circuit Rejects Teva’s Core Challenges to Medicare Drug Price Negotiation

Patient Advocates Applaud Another Major Legal Victory Protecting Medicare’s Power to Negotiate Lower Drug Prices WASHINGTON, D.C. — The U.S. Court of Appeals for the D.C. Circuit today rejected Teva Pharmaceuticals’ core statutory and constitutional challenges to the Medicare Drug Price Negotiation Program, delivering another significant legal victory for the historic program that is lowering prescription […]

Press Releases

STATEMENT: P4AD Warns Proposed Tariffs On Generic Drugs Would Raise Prices For Patients

WASHINGTON, D.C. — Last night, President Trump announced his plans to instate a 100% tariff on generic drugs beginning in August 2028, with a planned increase up to 200% in 2029, one year after his term ends. According to the president’s Truth Social announcement, the change will not impact brand-name drugs.  In response, P4AD CEO […]

Press Releases

STATEMENT: Patients For Affordable Drugs’ Statement on Supreme Court Decision Protecting Generic Competition

WASHINGTON, D.C. — Today, the U.S. Supreme Court unanimously ruled in favor of Hikma in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., preserving a critical pathway that allows lower-cost generic drugs to come to market. The case focused on “skinny labeling,” a long-standing process that allows generic manufacturers to seek approval for off-patent uses of medicines while still […]

Press Releases

NEW: Patient Advocates, Legal Experts React to Supreme Court Denying Pharma Lawsuits Challenging Medicare Drug Price Negotiation

WASHINGTON, D.C. — Following the Supreme Court’s decision this morning to decline petitions from AstraZeneca, Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, and Boehringer Ingelheim challenging the Medicare Drug Price Negotiation Program, Patients For Affordable Drugs and Public Citizen held a press briefing with a patient advocate and legal expert to discuss the implications for patients and the […]

Press Releases

The 2022 Prescription Drug Law Is Delivering Lasting Reductions in Prescription Drug Costs

WASHINGTON, D.C. — As debate continues around new proposals to lower prescription drug prices for Americans, one thing is clear: the 2022 prescription drug law is already helping to lower costs for millions of patients across the country. “The facts speak for themselves,” said Merith Basey, CEO of Patients For Affordable Drugs. “The Medicare drug price reforms are […]

Press Releases

From One Patient’s Story to 40,000: Patients For Affordable Drugs Reaches Major Milestone In Growing Patient Movement

WASHINGTON, D.C. — Patients For Affordable Drugs has reached a major milestone: more than 40,000 vetted patient stories are now on our interactive map, documenting the real-world harm caused by high drug prices. There are stories from every state and every congressional district in the country and the map allows users to explore stories by disease, ZIP code, and more, offering […]

Press Releases

P4AD Responds to Regeneron MFN Deal and Gene Therapy Approval 

WASHINGTON, D.C. — Regeneron is the latest drugmaker to reach a most-favored-nation (MFN) pricing agreement with the Trump administration, part of a broader set of voluntary deals aimed at bringing U.S. drug prices in line with those in other high-income countries. The company was the last of the 17 corporations that received letters in July […]

Press Releases

Patients For Affordable Drugs Responds to Trump’s Announcement On Tariffs

WASHINGTON, DC – Following President Trump’s announcement of sweeping tariffs of up to 100% on imported brand-name prescription drugs and their ingredients, Patients For Affordable Drugs CEO Merith Basey released the following statement: “While these tariffs aim to pressure pharmaceutical corporations into U.S. manufacturing and Most Favored Nation agreements, the current MFN deals remain opaque and voluntary, and have […]